

(1)	(2)	(3)	(4)	(5)	(6)	(7)
II. Doxycycline						
(i) I.D.P.L.	5.00	Basic	0.01	
(ii) Ranbaxy	2.50	„	0.68	1.66	4.32	
III. Erythromycin						
(i) I.D.P.L.	36.00	Basic	..	1.10	..	
(ii) Gujarat Themis Bioeyen	40.00	Intermediate	15.42	12.66	10.11	
(iii) Alembic Chemicals	12.00	Basic	14.70	17.75	9.00	
(iv) Standard Pharmaceuticals	6.00	„	
IV. Ampicillin						
(i) I.D.P.L.	35.00	Basic	1.00	0.26	3.7	
(ii) H.A.L.	35.00	„	14.18	8.38	13.56	
(iii) Ranbaxy	*55.50	Intermediate	44.89	45.03	65.70	
(iv) Alembic	5.00	Basic	2.42	2.48	1.65	
(v) Cadila Labs.	2.00	Intermediate	..	0.29	13.61	
(vi) Lyphin Chem.	..	„	6.45	
V. Amoxicillin						
(i) I.D.P.L.	25	Basic	3.90	5.10	1.30	
(ii) H.A.L.	
(iii) Sarabhai Chemicals	6	Basic	0.17	
(iv) Ranbaxy	*55.50	Intermediate	0.11	

*Overall capacity.

Bulk drugs under category I and II

2827. SHRI PRAVIN KUMAR PRAPATI: Will the Minister of INDUSTRY be pleased to state:

(a) names of the bulk drugs, which fall under category I and II Drugs Price Control Order being produced by Hoechst, Pfizer, Glaxo, Merck, Sharp, Roche, Ethenor, Geoffray Manner, Fairdeal Corporation, Wockhardt, F. Merck and Organon;

(b) what is the licensed capacity and what was the production during the last three years, yearwise of each drug;

(c) what is the price fixed of each by Government and charged by each of these companies;

(d) names of drug which fall under price exempted category produced by each of these companies along with licensed capacity and production during the last three years, yearwise ;

(e) names of formulations based on these drugs along with selling price of each during 1979 and 1985; and

(f) names of drugs where production exceeded than the permitted capacity which falls under category III and IV of these companies?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (b) A Statement giving the details of Category I and II bulk drugs produced by the

companies referred to and other details as asked for is attached.

(c) The prices fixed for the drugs under Drugs (Prices Control) Order, 1979 referred to in the Statement are given below:—

Sl. No.	Name of the Bulk Drug	Price fixed under DPCO, 1979 (Rs./Kg.)
1	Frusemide	1426.13
2	Tolbutamide	125.82
3	Sodium PAS	116.80

Based on the stay granted by the Delhi High Court M/s. Hoechst India Limited are charging a price of Rs. 1679.47 for Frusemide. In respect of other bulk drugs

no reports of overcharging of the prices have been received.

(d) to (f) Information to the extent available would be collected and laid on the Table of the Rajya Sabha.

Statement

(Figures in tonnes)

Sl. No.	Name of the Company	Name of the Bulk Drug	Licensed Capacity	Production during the last 3 years		
				1982-83	1983-84	1984-85
1	2	3	4	5	6	7
1	Hoechst India Limited	Frusemide	7.18	4.19	8.92	6.73
2	Do.	Tolbutamide	72	24.64	21.58	18.01
3	Pfizer Limited	Sodium PAS	110	12.60	3.67	8.52
4	Glaxo Labs.	Tripple Antigen	N.A.	1.20 (KL)	1.43 (KL)	1.50 (KL)

Sales turn over of vitamin preparations etc.

2828. SHRI PRAVIN KUMAR PRAJAPATI: Will the Minister of INDUSTRY be pleased to state:

(a) what was the annual sales turn over of vitamin preparations. Iron preparations, Appetite stimulants and tonics of Abbott, Glaxo, Pfizer, Bayer, Marind, Merck, Parke Davis, Hoechst and Titanor during the last three years, year-wise;

(b) what was the percentage of sales of above mentioned products of each heading of preparations to their total sales turn over during the above mentioned period;

(c) what was the price of each formulation of above mentioned preparations during 1980 and 1985;

(d) which are the products being marketed by these companies under price exempted category or without price approval along with name composition and therapeutic indication of each; and